Pharma major Lupin announced that it has received approval for its Albendazole Tablets USP, 200 mg, from the United States Food and Drug Administration (US FDA), to market a generic equivalent of Albenza Tablets, 200 mg, of Impax Laboratories.
Albendazole Tablets USP, 200 mg, are an anthelmintic drug indicated for treatment of:
- Parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm
- Cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm
Albendazole Tablets USP (RLD: Albenza) had an annual sales of approximately USD 34 million in the US (IQVIA MAT April 2020).